Teva and Alcobra Report Positive Data for ADHD Drug

Teva and partner Alcobra have reported new positive data on a candidate drug for attention-deficit hyperactivity disorder (ADHD) and have announced that they are planning to advance it to a full Phase III trials programme next year. The success of the Phase II trial of MG01CI, an extended release formulation of Metadoxine (pyridoxol L-2-pyrrolidone-5-carboxylate), has

Continue Reading